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In Brief
Pistorius et al., found that a recently uncovered family of bioactive mediators termed PD n-3 DPA controls human macrophage phenotype and function during their differentiation from monocytes. The authors also established the biosynthetic pathway for this family of mediators thereby providing leads into mechanisms that control macrophage responses.
INTRODUCTION
Macrophages are central in orchestrating host responses to tissue injury and infections (Fredman et al., 2014; Gordon and Mantovani, 2011; Pierdomenico et al., 2015) . The biological actions of these cells are associated with their phenotype, where classically activated macrophages are central in the initiation and propagation of the inflammatory response, whereas alternatively activated macrophages orchestrate tissue repair and regeneration Gordon and Mantovani, 2011; Morris et al., 2010) . Investigations into the cellular mechanisms underlying these distinct biological functions demonstrate that each macrophage subtype produces a characteristic repertoire of bioactive molecules, including cytokines and lipid mediators (LMs) Gordon and Mantovani, 2011) . In this context, recent studies demonstrate that, while classically activated macrophages and alternatively activated macrophages produce both inflammation initiating eicosanoids and pro-resolving mediators, their LM phenotypes differ. Indeed, classically activated macrophages produce higher amounts of pro-inflammatory eicosanoids, whereas alternatively activated macrophages produce higher levels of the recently identified specialized pro-resolving mediators (SPMs) (Dalli and Serhan, 2012) . Tissue macrophages arise during either embryonic development or are differentiated in situ from monocyte precursors (Kopf et al., 2015) . Mechanisms that dictate monocyte differentiation to different macrophage phenotypes are of relevance in determining whether inflammation is perpetuated or resolves, thus permitting regain of function.
SPMs are produced via the stereoselective conversion of essential fatty acids. The first SPMs identified were the lipoxins (LX) that are produced from arachidonic acid and carry potent leukocyte directed actions (Serhan et al., 1984) . The D-series resolvins (RvD) produced from docosahexaenoic acid (DHA) and the E-series resolvins (RvE) produced from eicosapentaenoic acid also display leukocyte-directed actions (Chiang and Serhan, 2017) . In addition, RvEs regulate platelet response (Dona et al., 2008) and neutrophil apoptosis (El Kebir et al., 2012) , while the RvDs regulate vascular smooth muscle cell migration, a key process in the development of intimal hyperplasia (Mottola et al., 2017) . Recently, we found that n-3 docosapentaenoic acid (DPA) is also a substrate for conversion to a new series of pro-resolving mediators, which include the n-3 DPA-derived protectins (PD n-3 DPA ) (Dalli et al., 2013a) . These mediators were initially identified in self-limited inflammatory exudates, with their production coinciding with monocyte/macrophage trafficking to the site. Human primary macrophages also produce these mediators. Of note, PD1 n-3 DPA and PD2 n-3 DPA carry potent leukocyte directed actions, reducing neutrophil recruitment as well as the production of inflammatory cytokines, including monocyte chemoattractant protein-1, during sterile inflammation (Dalli et al., 2013a) . These actions were also found with human primary cells, where PD n-3 DPA reduce human neutrophil-endothelial cell interactions, neutrophil chemotaxis, and increased macrophage phagocytosis. The complete stereochemistry of the first member of this family of mediators, PD1 n-3 DPA , was recently established as 10R,17S-dihydroxydocosa-7Z,11E,13E,15Z,19Z-pentaenoic acid (Aursnes et al., 2014) . In humans, PD1 n-3 DPA is upregulated in colon samples (A) Human monocytes were incubated with M-CSF (20 ng/mL) and either a ALOX15 inhibitor or vehicle (37 C, 5% CO 2 ). On day 7 incubations were quenched, lipid mediators were extracted, identified, and quantified using lipid mediator profiling (see the STAR Methods for details). Results are mean ± SEM. n = 6 donors. *p < 0.05. (B) Human monocytes were isolated and incubated with GM-CSF (20 ng/mL), IFN-g (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells, and the expression of ALOX15 and ALOX15B was evaluated during the differentiation time course using flow cytometry.
Results are mean ± SEM n = 4-6 donors per interval.
(legend continued on next page) from IBD patients and displays potent tissue protective actions in mice during experimental colitis, reducing leukocyte-mediated tissue damage (Gobbetti et al., 2017) . The PD n-3 DPA biosynthetic pathway in human monocytes and macrophages is proposed to be initiated by 15-lipoxygenases (LOX), which convert n-3 DPA to an intermediate epoxide that in turn is enzymatically hydrolyzed to PD1 n-3 DPA (Aursnes et al., 2014) and PD2 n-3 DPA (16,17R-dihydroxy-7Z,10,13,14,19Z-docosapentaenoic acid) (Dalli et al., 2013a) . Given the potent biological actions of PD n-3 DPA , and the central role of the proposed epoxide intermediate in the formation of these pro-resolving mediators, it was deemed important to (1) obtain evidence for its formation and role in the PD n-3 DPA biosynthesis, (2) establish the identity of enzyme(s) involved in the formation of this epoxide in human monocytes/macrophages, and (3) establish the biological actions of the PD n-3 DPA pathway in monocyte differentiation and macrophage responses. Using acid alcohol trapping, recombinant enzymes and human primary cells we found that both ALOX15 and ALOX15B catalyze the formation of 16,17S-ePD n-3 DPA . Using total organic synthesis we obtained stereochemically pure material, that, when incubated with primary human macrophages, was converted to both PD1 n-3 DPA and PD2 n-3 DPA . Furthermore, we found that the PD n-3 DPA pathway was important in regulating macrophage phenotype and function.
RESULTS

Inhibition of 15-Lipoxygenase Activity in Human
Monocytes Reduced Macrophage PD n-3 DPA Metabolome and Altered Macrophage Function To obtain evidence for the role of the PD n-3 DPA biosynthetic pathway in regulating human macrophage function during monocyte differentiation, we incubated monocytes with an ALOX15 inhibitor and assessed the production of components within the PD n-3 DPA pathway. In human primary cells, using liquid chromatography-tandem mass spectrometry (LC/MS-MS), we identified 17-HDPA, PD1 n-3 DPA , and PD2 n-3 DPA . In these incubations we also identified 10R/S,17S-diHDPA and 16R/S,17S-diHDPA, which correspond to the non-enzymatic products of the proposed epoxide intermediate in the PD n-3 DPA pathway ( Figure 1A ). Of note, incubation of monocytes with an inhibitor of ALOX15 led to a significant reduction in all the components of the PD n-3 DPA biosynthetic pathway, including the bioactive mediators PD1 n-3 DPA and PD2 n-3 DPA ( Figure 1A ; Table S1 ). The role of 15-lipoxygenases in PD n-3 DPA biosynthesis was further corroborated using cells from mice deficient in the murine homolog of this enzyme (ALOX15
), which demonstrated a significant reduction in all the components within the PD n-3 DPA pathway ( Figure S1 ; Table S2 ).
Human leukocytes express two ALOX15 subtypes, therefore we sought to determine the temporal regulation of these enzymes in circulating monocytes and during monocyte-macrophage differentiation. Flow cytometric analysis demonstrated that human circulating monocytes express both ALOX15 and ALOX15B. The expression of both enzyme isoforms was upregulated during monocyte-to-macrophage differentiation. Of note, ALOX15 expression was higher in M2 differentiated cells, whereas the expression of ALOX15B was higher in M1 cells ( Figure 1B) . We next investigated the contribution of each of these two enzymes to PD n-3 DPA biosynthesis in human monocytes. Here we found that transfection of human monocytes with short hairpin RNA (shRNA) to ALOX15 reduced enzyme expression by $50% (p < 0.05; n = 5 donors), and the concentrations of several components of the PD n-3 DPA biosynthetic pathway, including PD1 n-3 DPA and PD2 n-3 DPA . Transfection of monocytes with shRNA to ALOX15B significantly reduced both enzyme expression ($50%; p < 0.05; n = 5 donors) and PD n-3 DPA concentrations, albeit to a lesser extent than observed with shRNA to ALOX15 ( Figure S2 ).
Given that PD1 n-3 DPA and PD2 n-3 DPA carry potent biological actions, we next questioned whether inhibition of this pathway during monocyte-to-macrophage differentiation influenced macrophage phenotype and function. We therefore assessed the expression of phagocytic receptors and adhesion molecules, which are linked with macrophage phenotype. Incubation of cells with ALOX15 inhibitor during monocyte differentiation led to the downregulation of several lineage markers, including CD206, CD163, and CD64, and a shift in macrophage phenotype ( Figure 1C ). This downregulation in phagocytic receptors was of functional consequence since inhibition of the PD n-3 DPA biosynthetic pathway also significantly downregulated the ability of human macrophages to uptake apoptotic cells ( Figure 1D ), a key pro-resolving action (Chiang and Serhan, 2017; Dalli and Serhan, 2016) . This alteration in macrophage phenotype and function was also observed in tissue-resident macrophages from ALOX15-deficient animals. In these mice the expression of lineage markers on splenic macrophages, small peritoneal macrophages, and large peritoneal macrophages was altered with a downregulation in the expression of several markers including transforming growth factor b and T-cell immunoglubulin and mucin domain containing protein (TIM)-4 ( Figure 1E ). This was associated with a decreased ability of peritoneal macrophages to uptake apoptotic cells in vivo ( Figure 1F ; Table S3 ).
Having established a role of the PD n-3 DPA metabolome in regulating human macrophage function we next sought to obtain further evidence for the PD n-3 DPA biosynthetic pathway. Given the central role that the proposed 16,17S-ePD n-3 DPA plays in the biosynthesis of PD n-3 DPA , we sought to gain evidence for the formation of the proposed epoxide in human monocytes. For (C and D) Human monocytes were incubated with vehicle or ALOX15 inhibitor and then with M-CSF (20 ng/mL) for 7 days, and (C) expression of lineage markers was determined using fluorescently labeled antibodies and flow cytometry on day 7, and interrogated using OPLS-DA. n = 6 donors. (D) Phagocytosis of fluorescently labeled apoptotic cells investigated. Results for are mean ± SEM. n = 6 donors. *p < 0.05. (E) Peritoneal macrophages were harvested from wild-type (WT) and ALOX15 À/À mice, and the expression of lineage markers on CD64 + cells was determined using flow cytometry. Results were interrogated using OPLS-DA and are representative of n = 7 mice. (F) Fluorescently labeled apoptotic cells were administered to WT and ALOX15 À/À mice via intraperitoneal injection. After 1 hr peritoneal cells were harvested, and phagocytosis of apoptotic cells by CD64 + cells was evaluated using flow cytometry. Results are mean ± SEM. n = 7 mice per group. *p < 0.05.
Related to Figures S1 and S2 and Tables S1-S3. this purpose we assessed the formation of the epoxide using acid alcohol trapping, given that allylic epoxides are known to be unstable in aqueous solutions (Radmark et al., 1980) . Using LC/MS-MS we identified four peaks, the first two gave a retention time (T R ) and MS-MS fragmentation spectra corresponding with 10-methoxy,17S-hydroxy-docosapentaenoic acid (Figure 2A) , whereas, the T R and MS-MS spectra for peaks III and IV corresponded to 16-methoxy,17S-hydroxy-docosapentaenoic acid (Figure 2A ). Having obtained evidence for the formation of an epoxide intermediate by human monocytes we sought to determine whether ALOX15 enzymes were responsible for the formation of this intermediate. For this purpose we incubated human recombinant (hr) ALOX15 and hr-ALOX15B with n-3 DPA and assessed the acid alcohol trapping products using LC/MS-MS. This also gave four peaks that displayed essentially identical T R and MS-MS fragmentation spectra to the products obtained with primary human macrophages ( Figures 2B and 2C) . Thus, these results establish the role of human ALOX15 enzymes in the formation of 16,17S-ePD n-3 DPA .
Establishing the Complete Stereochemistry of 16S,17S-ePD n-3 DPA Having obtained evidence for the formation of 16,17S-ePD n-3 DPA by human monocytes and the role of ALOX15 enzymes in its production, we next sought evidence for its role in the biosynthesis of PD1 n-3 DPA and PD2 n-3 DPA . For this purpose we obtained stereochemically pure material using total organic synthesis. The methyl ester of 16S,17S-ePD n-3 DPA was constructed via two key precursors ( Figure 3A ). These precursors were obtained using the following stereoselective reactions: a Katsuki-Sharpless epoxidation protocol (Kumar and Meshram, 2013) and one Z-and two E-selective Wittig reactions (Maryanoff and Reitz, 1989) . The detailed description of the synthetic route is reported in Primdahl et al. (2017) . The chemical purity and stereochemical integrity was validated using LC/MS-MS and nuclear magnetic resonance (NMR of the synthetic epoxide as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid methyl ester.
We next assessed whether the physical properties of the synthetic material obtained after lenient hydrolysis of the epoxy methyl ester matched those of the biological material. Incubation of the synthetic material in acid alcohol gave four distinct peaks with products displaying essentially identical T R and MS-MS fragmentation spectra as those obtained with hr-ALOX15 enzymes and human monocytes (Figures 2 and S4 ).
We next investigated whether the synthetic material was substrate for conversion to PD1 n-3 DPA and PD2 n-3 DPA . To this end, human macrophages were incubated with 16S,17S-ePD n-3 DPA and products were assessed using LC/MS-MS. In multiple reaction monitoring (MRM) we obtained two peaks. The first peak eluted with a T R of 13.8 min and gave characteristic fragments in the MS-MS that are consistent with PD1 n-3 DPA. These fragments included the following diagnostic ions: m/z 361, m/z 183, and m/z 155 (Figures 4A and 4B). The second peak eluted with a T R of 15.2 min and gave ions in the MS-MS that were characteristic of PD2 n-3 DPA including: m/z 361, m/z 263, and m/z 233 ( Figures 4A and 4C ). Of note, incubation of 16S,17S-ePD n-3 DPA in PBS only or with cells that had been previously kept at 100 C did not yield notable levels of these mediators ( Figure 4D ), indicating that the conversion of the epoxide to PD1 n-3 DPA and PD2 n-3 DPA was reliant on enzyme-mediated catalysis. In addition, these results establish the stereochemistry of the allylic epoxide intermediate as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid.
Epoxide Hydrolases Convert 16S,17S-ePD n-3 DPA to PD1 n-3 DPA and PD2 n-3 DPA Having established a role for enzymes in catalyzing the conversion of 16S,17S-ePD n-3 DPA to PD1 n-3 DPA and PD2 n-3 DPA we next sought to establish the identity of these enzymes. Given the role that epoxide hydrolases play in converting allylic epoxides to bioactive mediators we assessed whether this class of enzymes was also involved in catalyzing the conversion of 16S,17S-ePD n-3 DPA in human monocytes. Incubation of human macrophages with the epoxide hydrolase inhibitor AUDA led to a reduction in the concentrations of both PD1 n-3 DPA and PD2 n-3 DPA ( Figure 5A ). Relative Intensity (%) Leukotriene A 4 hydrolase (LTA 4 H) catalyses the hydrolysis of the allylic epoxide in LTA 4 at the least sterically hindered carbon of the carbocation intermediate (Radmark et al., 1980; Rudberg et al., 2002) and is also expressed by human macrophages (Qiu et al., 2006) . Therefore we questioned whether this enzyme was also responsible for catalyzing the conversion of 16S,17S-ePD n-3 DPA to PD1 n-3 DPA . LC/MS-MS analysis of products obtained when LTA 4 H was incubated with Figure 6 . EPHX2 Converts 16S,17S-ePD n-3 DPA to PD2 n-3 DPA in Human Monocytes and Macrophages (A) Human monocytes were isolated and differentiated using GM-CSF (20 ng/mL), IFN-g (20 ng/mL), and LPS (100 ng/mL) to produce M1 or M-CSF (20 ng/mL) and IL-4 (20 ng/mL) to obtain M2 cells and the expression of EPHX2 during the differentiation time course was evaluated using flow cytometry. Results are mean ± SEM. n = 4-6 donors per interval. (B) Human monocytes were transfected with shRNA to EPHX2 or CT shRNA (see the STAR Methods for details), cells were incubated for 10 hr at 37 C, then with E. coli for 45 min, and PD n-3 DPA concentrations evaluated using LM profiling. Results are mean ± SEM. n = 4 donors. *p < 0.05. (C) 16S,17S-ePD n-3 DPA (10 nM) was incubated with hrEPHX2 (0.2 mM; Tris buffer). Incubations were quenched using ice-cold methanol and products identified using lipid mediator profiling. 16S,17S-ePD n-3 DPA gave four peaks that were identified as the non-enzymatic hydrolysis products of 16S,17S-epoxy-PD n-3 DPA . The T R and MS-MS spectra of peaks I and II corresponded to 10R/S,17S-dihydroxy-7Z,11E,13E,15E,19Z-docosapentaenoic acid, whereas peaks III and IV were identified as 16R/S,17S-dihydroxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid ( Figure 5B ). For comparison LM profiling of the products obtained when LTA 4 H was incubated with LTA 4 gave a major peak that eluted with a T R of 13.6 min, with the MS-MS spectrum corresponding to LTB 4 (n = 4 incubations). Another epoxide hydrolase expressed by human macrophages, which is also involved in the catalysis of allylic epoxides to bioactive mediators, is epoxide hydrolase 2 (EPHX2) (Deng et al., 2014) . Thus, we next investigated whether this enzyme may play a role in the PD n-3 DPA biosynthetic pathway. Using flow cytometry we found that EPHX2 is expressed in monocytes and is upregulated during monocyte-to-macrophage differentiation ( Figure 6A ). Transfection of human monocytes with shRNA to EPHX2 led to a significant downregulation of PD2 n-3 DPA and an increase in PD1 n-3 DPA concentrations ( Figure 6B ). To further validate the role of EPHX2 in PD2 n-3 DPA biosynthesis, we incubated hr-EPHX2 with 16S,17S-ePD n-3 DPA , which gave a peak with T R of 15.2 min and an MS-MS spectrum that corresponded to that of PD2 n-3 DPA ( Figure 6C ). Of note, in these incubations we did not identify PD1 n-3 DPA , suggesting that this enzyme selectively catalyzed the conversion of 16S,17S-ePD n-3 DPA to PD2 n-3 DPA . Having found that hr-EPHX2 converted the epoxide to PD2 n-3 DPA , we next co-incubated hr-ALOX15 with hr-EPHX2 to obtain further evidence for the PD2 n-3 DPA biosynthetic pathway in human cells. LM profiling of these incubations gave a peak with T R and MS-MS spectrum corresponding to PD2 n-3 DPA ( Figure 6D ). Of note, levels of this mediator in incubations with either hr-ALOX15 or EPHX2 were negligible. Similar findings were also made with incubations of hr-ALOX15B and EPHX2 (n = 3 distinct incubations). To further assess the role of EPHX2 in the biosynthesis of PD2 n-3 DPA we incubated this enzyme with increasing concentrations of 16S,17S-ePD n-3 DPA and determined the reaction kinetics. Here we found that 16S,17S-ePD n-3 DPA was rapidly converted with a V max of 3,439 ± 1,539 mmol/min and a K M of 332 ± 188 mM ( Figure 6E) . Together these findings demonstrate that epoxide hydrolase enzymes are key in the conversion of 16S,17S-ePD n-3 DPA to PD1 n-3 DPA and PD2 n-3 DPA , and identify EPHX2 as the enzyme responsible for the conversion of 16S,17S-ePD n-3 DPA to PD2 n-3 DPA .
PD n-3 DPA Regulate Human Macrophage Phenotype and Responses Having found that inhibition of the PD n-3 DPA pathway alters macrophage phenotype we next sought to determine the role of select members of the PD n-3 DPA pathway during monocyte-to-macrophage differentiation. Co-incubation of human macrophages with an ALOX15 inhibitor and either 16S,17S-ePD n-3 DPA or PD1 n-3 DPA upregulated the expression of several lineage markers, including CD163 and CD64, when compared with cells incubated with the inhibitor alone ( Figure S5A ). We next investigated whether the upregulation of these lineage markers was also associated with a restoration of the ability of human macrophages to clear apoptotic cells. Indeed, incubation of monocyte-dervied macrophages with 16S,17S-ePD n-3 DPA or PD1 n-3 DPA rectified their ability to uptake apoptotic cells ( Figures  S5B and S5C ). These restorative actions of PD n-3 DPA on macrophage function were also retained in vivo, where administration of PD1 n-3 DPA rectified the expression of lineage markers on both splenic and peritoneal macrophages from ALOX15 À/À mice (Figures 7A-7C ; Table S3 ). Furthermore PD1 n-3 DPA also upregulated the ability of peritoneal macrophages from ALOX15 À/À mice to uptake apoptotic cells ( Figure 7D ) and bacteria (Figure 7E ) in vivo. Together, these results demonstrate that the PD n-3 DPA pathway regulates key human macrophage functions in promoting the resolution of inflammation.
DISCUSSION
Herein, we established the PD n-3 DPA biosynthetic pathway and the role of this pathway in regulating key macrophage responses during monocyte-to-macrophage differentiation. Results from the present experiments demonstrate that, in human and mouse monocytes and macrophages, 15-lipoxygenases are the initiating enzyme in the PD n-3 DPA pathway catalyzing the formation of 17S-HpDPA and 16S,17S-ePD n-3 DPA . The epoxide is then converted via enzymatic hydrolysis to PD1 n-3 DPA and PD2 n-3 DPA , whereby the conversion of 16S,17S-ePD n-3 DPA to PD2 n-3 DPA is catalyzed by EPHX2. Inhibition of ALOX15 activity led to a significant alteration in the expression of lineage markers as well as the ability of macrophages to uptake apoptotic cells and bacteria, actions that were recovered by either 16S,17S-ePD n-3 DPA or PD1 n-3 DPA .
During acute inflammation, monocytes are recruited to the site where under ideal conditions, they differentiate to macrophages with a tissue protective phenotype; a process that is central in the resolution of inflammation as well as tissue repair and regeneration (Bystrom et al., 2008; Dalli and Serhan, 2016) . Chronic, unresolved inflammation is associated with dysregulated monocyte differentiation leading to macrophages displaying a pro-inflammatory phenotype Newson et al., 2014; Sica et al., 2000) . The mechanisms dictating whether monocytes differentiate into a tissue reparative or pro-inflammatory phenotype remain of interest. In the present study, we found that inhibiting ALOX15 expression and activity using both genetic and pharmacological approaches in mice and human primary cells dysregulated both macrophage phenotype and function (Figure 1) . Incubation of monocytes throughout their differentiation into macrophages À/À mice administered PD1 n-3 DPA (10 ng/mouse for 7 days) or vehicle and WT mice using flow cytometry and macrophage phenotype interrogated using PLS-DA in (A) large peritoneal macrophages, (B) small peritoneal macrophages, and (C) splenic macrophages. Results are representative of n = 8 mice per group for (A and B) and n = 3-4 mice per group for (C).
(legend continued on next page)
with either 16S,17S-ePD n-3 DPA or PD1 n-3 DPA rescued the ability of macrophages to uptake apoptotic cells as well as upregulated the expression of lineage markers, including CD64 and CD163, which were decreased following ALOX15 inhibition. PD1 n-3 DPA administration to ALOX15-deficient mice also rectified the expression of lineage markers on tissue-resident macrophages and the ability of peritoneal macrophages to uptake apoptotic cells and bacteria (Figure 7 ). Of note, ALOX15 is also the initiating enzyme in the RvD and LX biosynthetic pathway. Thus, while these results do not rule out the contribution of other ALOX15-derived pro-resolving mediators in the regulating monocyte-to-macrophage differentiation, they support a role for the PD n-3 DPA metabolome in regulating this process. The present findings also suggest that 16S,17S-ePD n-3 DPA is both a biosynthetic intermediate in the PD n-3 DPA pathway and exerts independent biological actions regulating cellular functions. These results are in line with findings made with other allylic epoxides including LTA 4 (Ohishi et al., 1987) and 13S,14S-epoxy-maresin (Dalli et al., 2013c) , which are also bioactive, regulating LM biosynthesis and cellular phenotype. LMs are produced via the stereoselective conversion of essential fatty acids by their biosynthetic enzymes. Recent studies demonstrate that the differential regulation of the SPM biosynthetic enzymes may reflect disease status and contribute to the propagation of ongoing inflammation. In this context, for example, Fredman et al. (2014) found that phosphorylation of the ALOX5 changes the product profile of the enzyme, whereby phospho-ALOX5 translocates to the nuclear membrane where it couples with phospholipase A 2 and LTA 4 H to produce the potent leukocyte chemoattractant LTB 4 . In the absence of this phosphorylation the enzyme is found in the cytosol, where it couples with ALOX15, producing the tissue-protective and pro-resolving mediators RvD1 and LXA 4 (Fredman et al., 2014) . These mechanisms are linked with disease onset/progression whereby, in atherosclerosis, recent studies identified an increased expression of phosphorylated ALOX5 and a decrease in the RvD1 to LTB 4 ratio in aortic lesions (Fredman et al., 2016) . These results may also shed light on the apparently discordant results obtained with omega-3 supplementation. This is because, if the expression and/or subcellular localization of SPM biosynthetic enzymes is dysregulated, the product profile will be altered and the expected beneficial actions via SPM production may be diminished. Thus, furthering our understanding on the biosynthetic pathways governing SPM biosynthesis is essential in order to gain better insights into disease etiopathology. The present studies focus on establishing the role of the PD n-3 DPA in cells of the monocytic lineage. These findings demonstrate that human ALOX15 and ALOX15B catalyze the first two steps in the PD n-3 DPA biosynthetic pathway yielding an allylic epoxide. Using total organic synthesis, we established the absolute stereochemistry of this epoxide as 16S,17S-epoxy-7Z,10Z,12E,14E,19Z-docosapentaenoic acid. Furthermore, using this synthetic material we found that 16S,17S-ePD n-3 DPA was converted to PD1 n-3 DPA and PD2 n-3 DPA by different epoxide hydrolase enzymes, where in human cells EPHX2 was found to catalyze the conversion of 16S,17S-ePD n-3 DPA to PD2 n-3 DPA (Figure 7 ). Of note, we also found that LTA 4 H was not involved in the biosynthesis of PD1 n-3 DPA .
In summation, the present findings establish the identity of enzymes involved in the PD n-3 DPA biosynthetic pathway, as well as the complete stereochemistry of the key intermediate in this pathway ( Figure 7F ). They also demonstrate that the PD n-3 DPA pathway plays a role in the differentiation of monocytes to macrophages, where inhibition of 15-lipoxygenase activity during monocyte-to-macrophage differentiation results in impaired monocyte-derived macrophage responses that are rescued by addition of PD n-3 DPA . Thus, these findings establish candidates in understanding the etiopathology of inflammatory diseases as well as targets for patient stratification and essential fatty acid supplementation.
SIGNIFICANCE
Macrophages are central players in controlling the body's response to both sterile injury and infections. During the course of inflammation monocytes are recruited to the site of injury and/or infections, where they differentiate to macrophages. The phenotype displayed by these macrophages dictates whether the cells promote the termination of inflammation or lead to chronicity, with the mechanisms that control the monocyte-to-macrophage differentiation process remaining of interest. In the present study, we found that inhibition of ALOX15 activity during monocyteto-macrophage differentiation reduced PD n-3 DPA production, altered human macrophage phenotype and their ability to clear dead cells, a key step in the termination of inflammation. Incubation of these cells with components of the PD n-3 DPA biosynthetic pathway rectified these responses. We established the identity and complete stereochemistry of 16S,17S-ePD n-3 DPA , a key intermediate in this pathway, and the role of human 15-lipoxygenases in producing this intermediate. We also provide evidence for a role of epoxide hydrolase enzymes in catalyzing the conversion of this intermediate to the pro-resolving mediators PD1 n-3 DPA and PD2 n-3 DPA in human monocytes. Here we found that EPHX2 selectively catalyzes the conversion of 16S,17S-ePD n-3 DPA to PD2 n-3 DPA . Together these results establish the PD n-3 DPA pathway in human monocytes and the contribution of this pathway in monocyte-to-macrophage differentiation. 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Studies Healthy 6-11 week old male C57/Black6 wild type mice (Charles River) and ALOX15 -/-(The Jackson Laboratory) mice were used in the reported studies. The experiments strictly adhered to UK Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986) and Laboratory Animal Science Association (LASA) Guidelines (Guiding Principles on Good Practice for Animal Welfare and Ethical Review Bodies, 3rd Edition, 2015) . Animals were kept on a 12 h light dark cycle, with lights turned on at 7:00 h and lights turned off at 19:00h under specific pathogen free housing and had access to food and water ad libitum. Sample size was based on the statistical analysis of previous experiments and no mice were excluded. Animals were randomly assigned to control and experimental groups. The investigators were not blinded to group assignments.
Human Primary Cells
Healthy human peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte cones obtained from the NHS Blood and Transplant bank and experiments were conducted in accordance with a protocol approved by Queen Mary Research Ethics Committee (QMREC 2014:61) and in accordance with the Helsinki declaration. Informed consent was obtained from all volunteers. Given that cones were obtained from the NHS Blood and Transplant bank and volunteers were unidentified, no information was available on sex, age, their involvement in previous experiments or if they were drug or test naïve. Primary cells were incubated for at 37 C at 5 % CO 2 . The HL60 cell line was established in a female donor.
METHOD DETAILS Monocyte Incubations
Human PBMCs were isolated from healthy human volunteers purchased from the NHS Blood and Transplant bank and experiments conducted in Queen Mary Research Ethics Committee approval (QMREC 2014:61) and the Helsinki declaration.
Here blood cones were used and PBMCs were isolated by density centrifugation where cells were layered on to Histopaque -1077 (Sigma) and centrifuged for 30 minutes at 400 x g at room temperature (RT). Macrophages were prepared using published protocols (Dalli and Serhan, 2012) where PBMCs were plated into 10 cm tissue culture plates and incubated at 37 C for 30 min in PBS +/+ . Non-adherent cells were then removed by adding PBS -/-and washed vigorously. Adherent cells (3 3 10 7 cells/incubation) were then incubated with vehicle (PBS+0.1% ethanol), 1 nM 16S,17S-ePD n-3 DPA or 1 nM PD1 n-3 DPA in RPMI 1640 (Sigma) for 30 minutes at 37 C. These were then incubated with either vehicle or ALOX15 inhibitor (10 mM PD146176 (Sendobry et al., 1997) ; Cambridge Bioscience) in RPMI 1640 containing 10% human serum, 1% Penicillin-Streptomycin and 20 ng/mL M-CSF. The cells were incubated for 3 days at 37 C at 5% CO 2 and the media together with mediators and inhibitors were added as above and the cells were incubated a further 4 days. For lipid mediator profiling of cell supernatant, RPMI 1640 Medium (no glutamine) with no phenol red was used. Cell supernatants were collected and placed in two volumes of methanol containing deuterium labelled internal standards (500 pg of d 4 -Prostaglandin (PG)E 2 , d 5 -LXA 4 , d 4 -RvD2, d 4 -Leukotriene (LT)B 4 and d 8 -5S-Hydroxy-eicosatetraneoic acid; Cayman Chemicals). These were stored at -20 C until extraction (see below). In select experiments to obtain M1 macrophages adherent cells were cultured with GM-CSF (20ng/mL) for 6 days then with LPS (1ng/mL) and interferon-g (20ng/mL) for 24h. To obtain M2 macrophages adherent cells where incubated with M-CSF (20ng/mL) for 7 days then with IL-4 (20ng/mL) for 48 h. In all cases the purity of the cell preparations ranged between 90-95%.
For human monocyte incubations we isolated monocytes from PBMCs using the EasySepÔ Human Monocyte Isolation Kit, following manufacturer's instruction where the purity of the resultant cell population was of $95%. Human monocytes (1 3 10 8 cells/mL) were incubated with n-3 DPA (10mM) and Escherichia coli (5 3 10 9 CFU/mL) in PBS at 37 C. Incubations were quenched -[[(tricyclo[3.3.1.13,7] dec-1-ylamino)carbonyl]amino]-dodecanoic acid (AUDA; 25mM) for 20 min at RT. Cells were then incubated with either vehicle (PBS + 0.1%EtOH) or 16S,17S-e-PD n-3 DPA (10nM) for 15 min. Incubations were then quenched and products identified and profiled using LM profiling as detailed below. Monocytes (1.5x10 6 cells/ml) were suspended in phenol red free RPMI 1640 containing 10% human serum, 8mg/ml of polybrene and 50ng/ml of shRNA to ALOX15B or CT shRNA. The cell suspension was then centrifuged at 1000 x g for 90 min at 4 C. Cells were then plated and incubated for a further 12h at 37 C. Monocytes were then detached after 5 minutes incubation in 2mM EDTA in PBS -/-, and the expression of ALOX15B was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with E. coli (1:50 monocytes to bacteria) for 45 min at 37 C. Incubations were quenched using two volumes of ice-cold methanol and products profiled using lipid mediator profiling.
In separate experiments monocytes were plated in 6 well plates and incubated with phenol red free RPMI 1640 containing 10% human serum, 8mg/ml of polybrene and 2mg/ml of shRNA to ALOX15, EPHX2 or CT shRNA. The cell incubations were gently mixed for the first 5 hours, media was then removed and cells incubated with 15% DMSO in Hanks' Buffered Saline Solution for 4 mins at 37 C. The solution was then removed, cells were rinsed with PBS and then incubated for a further 7h in phenol red free RPMI containing 10% human serum and 1% Penicillin-Streptomycin. Cells were then detached after 5 minutes incubation in 2mM EDTA in PBS -/-, and expression of ALOX15 and EPHX2 was evaluated using flow cytometry. Cells were also suspended in PBS containing 0.1% human serum and incubated with E. coli as detailed above.
Mouse monocytes were isolated by adhesion of bone marrow cell suspension from WT and ALOX15-deficient mice to tissue culture dishes. After 45 min cell were detached and cell populations determined to be $80-90% monocytes. Monocytes (2 3 10 6 cells/mL) were incubated in phenol red free RPMI containing 0.1% FBS and E. coli (1 3 10 8 CFU/mL) at 37 C for 45 min. Incubations were quenched using 2 volumes of ice-cold methanol containing deuterium labelled internal standards and lipid mediators identified and quantified using lipid mediator profiling.
Enzyme Incubations
Human recombinant (hr)-ALOX15 (0.2mM; Novus Biologicals) or (hr)-ALOX15B (0.2mM; Cayman Chemicals) was incubated with n-3 DPA (10 mM) in Tris buffer (pH = 8.0) at RT for 2 min. Products were quenched using excess acidified methanol (apparent pH $3) containing deuterium labelled d 4 -LTB 4 and extracted as detailed in the lipid mediator profiling section below. In select incubations hr-ALOX15 or hr-ALOX15B were incubated with EPHX2 (0.2mM; Cayman Chemicals) and n-3 DPA (10mM) in Tris buffer (pH = 8.0) at RT for 15 min. Incubations were quenched using ice-cold methanol and products extracted, identified and quantified as detailed below.
In select incubations EPHX2 (0.2mM) was incubated with 16S,17S-ePD n-3 DPA (10nM) in Tris buffer (pH = 8.0) at RT for 10 min; incubations were then quenched, and products identified and quantified as detailed below.
Flow Cytometry
Flow cytometry was used to determine the phenotypic lineage of the monocyte-derived macrophages using fluorescently conjugated antibodies. Cells were fixed in 1% paraformaldehyde (4% paraformaldehyde in PBS -/-) for 10 minutes at room temperature. Cells were incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4 C in staining solution (1:1 PBS with 0.02 % BSA and FC block): APC/Cy7 anti-human CD14 (clone 63D3, Biolegend), PE-Cyanine7 anti-human CD32 (clone 6C4, eBiosciences), Alexa Fluor (AF) 405 anti-ICAM-1 (clone 1A29, Novus), PE/Cy5 anti-CD64 (clone 10.1, Abcam), AF 488 anti-human CD68 (clone Y1/82A, Biolegend), Brilliant Violet (BV) 650 anti-human CD80 (clone 2D10, Biolegend), PerCP/Cy5.5 anti-human CD206 (clone 15-2, Biolegend) and PE-CF594 anti-human CD163 (clone GHI/61, BD Biosciences). LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter analysis, followed by analysis using FlowJo (Tree Star Inc., V10).
To determine the expression of PD n-3 DPA biosynthetic enzymes, monocytes and macrophages were incubated with M-CSF and IL-4 or GM-CSF, IFNg and LPS for 7 days as detailed above. At the indicated intervals cells were collected, permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer's instructions, non-specific binding was quenched using non-specific IgG (16mg/mL) and cells were then incubated with rabbit anti-human 15-LOX type 1, mouse anti-human 15-LOX type 2, and mouse anti-human EH2 for 30 min at 4 C. To determine the expression of 15-LOX type 2 and EH2, cells were then incubated with AF 488 goat anti-mouse IgG for 30 min at 4 C and staining evaluated using LSR Fortessa cell analyser (BD Biosciences) was used to perform multiparameter data acquisition, followed by analysis using FlowJo (Tree Star Inc., V10).
In select experiments cells were collected from the peritoneum of WT and ALOX1-deficient mice by lavaging the peritoneum with PBS. Splenic cells were obtained following dissociation of spleens from WT and ALOX15-deficient mice using a 70 mM filter. The cells were counted and incubated with the following antibodies in a 1:100 dilution for 30 minutes at 4 C in staining solution (1:1 PBS with 0.02 % BSA and TrueStain FC Blocking IgG): PE-Cy5 anti-mouse/human CD 11b (Clone M1/70, Biolegend), BV 650 rat anti-mouse I-A/I-E (MHC II) (Clone M5/114.15.2, Biolegend), APC-Cy7 rat anti-mouse F4/80 (Clone BM8, Biolegend), BV785 hamster anti-mouse CD 11c (Clone N418, Biolegend) and PerCP-eFluor710 rat anti-mouse TIM-4 (Clone 54 (RMT4-54), eBiosciences). For intracellular staining, cells were permeabilized using eBiosciences Fixation/ Permeabilization Solution Kit following manufacturer's instructions for 20 min at RT and then with fluorescently labelled antibodies in a 1:50 dilution for 30 minutes at 4 C in staining solution
(1:10 Permeabilization buffer (10X) (eBiosciences) and PBS with 0.02 % BSA): AF 488 COX 2 (Clone (D5H5) XP Ò, Cell Signaling Technologies), PE-Dazzle 594 rat anti-mouse IL-10 (Clone JES5-16E3, Biolegend), BV 421 mouse anti-mouse TGF-b1 (Clone TW7-16B4, Biolegend), PE sheep anti-mouse Arginase 1 (Cat # IC5868P, R&D) and AF 647 rabbit-anti-human iNOS (Clone 4E5, Novus). Non-specific binding was quenched using TruStain Fc-blocking IgG (anti-mouse CD16/32) and the staining was evaluated as above. For cells obtained from both in vivo efferocytosis and phagocytosis experiments non-sepcific binding was quenched as detailed above. Cells were then incubated in PBS -/-containing 0.02% BSA and either APC-Cy anti-mouse CD64 or PE anti-mouse CD64 (at 1:100 dilution) for 30 min at 4 o C and staining evaluated.
Macrophage Incubations
In Vitro Efferocytosis Macrophages, prepared as described above, were seeded into 96 well plates at 5 3 10 4 cells per well in RPMI 1640 medium with 10 % human serum at 37 C. Apoptotic cells were prepared by incubating the human promyelocytic leukemic cell line HL60 at 70 C for 2h yielding $60% Annexin V positive / propidium iodide negative cells and 35% Annexin V positive / propidium iodide positive cells using APC Annexin V Apoptotic Detection Kit with PI (Biolegend). These were then stained using PKH26 Red Fluorescent Cell Linker kit (Sigma) following manufacturer's instructions and efferocytosis was assessed as in (Dalli and Serhan, 2012) . In brief, fluorescently labelled apoptotic cells (1:3, macrophages to apoptotic cells) were added to the macrophages and incubated at 37 C for 45 minutes. Cells were washed with PBS and extracellular fluorescence was quenched using trypan blue (1:15 in PBS). Fluorescence was then measured using a FLUOstar Omega microplate reader (BMG Labtech). In select experiments apoptotic cells were labelled using PKH67 and incubated with macrophages as detailed above. Macrophage efferocytosis was then evaluated using an ImageStream X MK2 and analysis was performed using IDEASÒ (Image Data Exploration and Analysis Software, Version 6.0).
In Vivo Efferocytosis
Mice were administered either vehicle or PD1 n-3 DPA (10ng/mouse) via i.p. injection for 7 days. Apoptotic cells were prepared and labelled as detailed above using PKH67 dye. These (6x10 6 cells per mouse) were injected via intraperitoneal injection to Sample sizes for each experiment were determined on the variability observed in prior experiments and preliminary experiments. Partial least squares-discrimination analysis (PLS-DA) and principal component analysis (PCA) (Janes and Yaffe, 2006) were performed using SIMCA 14.1 software (Umetrics, Umea, Sweden) following mean centering and unit variance scaling of LM levels. PLS-DA is based on a linear multivariate model that identifies variables that contribute to class separation of observations on the basis of their variables (LM levels). During classification, observations were projected onto their respective class model. The score plot illustrates the systematic clusters among the observations (closer plots presenting higher similarity in the data matrix). Loading plot interpretation identified the variables with the best discriminatory power (Variable Importance in Projection greater than 1) that were associated with the distinct intervals and contributed to the tight clusters observed in the Score plot.
DATA AND SOFTWARE AVAILABILITY
Data are available upon request to the Lead contact.
